Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

DRG 001 addresses heart transplant or implantation of a heart assist system with Major Complication or Comorbidity, encompassing the most complex cardiac surgical admissions. This Diagnosis-Related Group is critical for inpatient reimbursement because it represents high resource utilization and significantly impacts Medicare payment determinations.

Customize your policy alerts

Sign up for drg 001 policy alerts

Get alerted when payer policies referencing 001 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 001 Overview

DRG 001 covers inpatient admissions for heart transplant or implantation of a heart assist system with Major Complication or Comorbidity. This Diagnosis-Related Group captures the highest complexity cardiac surgical cases that drive substantial resource use, including postoperative intensive care and prolonged hospitalization. It matters for Medicare payment because it represents one of the most resource-intensive Diagnosis-Related Groups, influencing base payment, outlier considerations, and hospital financial planning. Precise coding of diagnoses and procedures determines assignment to this Diagnosis-Related Group and consequent reimbursement tiers.

Explore openpayer tools

View all tools

Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

Customize your policy alerts

Sign up for drg 001 policy alerts

Get alerted when payer policies referencing 001 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 001 Overview

National Payment Rates

Across national payers the observed rate range spans roughly $170K to $990K, with Anthem and Blue Cross Blue Shield showing the highest maximums. The widest spread between a payer’s minimum and maximum is seen with Anthem (up to $990K). See the table and chart below for payer-specific quartiles and medians for Anthem, Aetna, Cigna, and BCBS.

The CMS 2023 dataset reflects national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($332.9k), average submitted covered charges ($1.5m), average Medicare payment ($281.5k), and total discharges (2.0k).

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$330K	$1.5M	$280K	2K

Patient Population

This DRG’s population includes both Medicare-age beneficiaries and non-Medicare commercial enrollees, producing a mixed-age payer mix skewed toward older adults. Many admissions are covered by Medicare fee-for-service, but a substantial share comes from private/commercial payers such as Aetna, Anthem, Cigna and BCBS. The overall payer mix therefore reflects a combination of Medicare-age and working-age patients rather than exclusively one group.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska for DRG 001, mean rates across payers range from $440K to $490K, with Cigna at the top end and Anthem and Blue Cross Blue Shield at the low end. This represents a narrow state-level spread and a modest elevation above some national averages at the top payer. See the table and chart below for payer-specific distribution and percentile detail.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska at a mean of $490K, while Anthem and Blue Cross Blue Shield are tied as the lowest payers at a mean of $440K.
The statewide mean range spans from $440K to $490K, a relatively tight band compared with national variability; Alaska’s highest mean ($490K) modestly exceeds the national mean benchmarks shown but the lowest means ($440K) align with national medians, indicating limited upside in the market.

Clinical Trials

Perioperative management and device optimization trials: These studies focus on immediate intraoperative and early postoperative strategies for heart transplant recipients and patients receiving durable or temporary mechanical circulatory support devices, investigating protocols for anticoagulation timing, hemodynamic support algorithms, infection prophylaxis, and strategies to minimize right ventricular failure after device implantation. The patient population includes adults undergoing orthotopic heart transplantation or implantation of left ventricular assist devices (LVADs) or temporary extracorporeal support, often with multiple organ dysfunction or high surgical risk. Results are relevant to providers for improving survival and complication rates in the index hospitalization and to payers because optimized perioperative protocols can reduce intensive care length of stay, device-related complications, and readmissions that drive high costs under this DRG.
Comparative effectiveness studies of long-term support versus transplantation candidacy: These trials compare outcomes between patients who proceed to durable mechanical circulatory support as destination therapy or bridge-to-transplant versus those listed for transplantation, assessing survival, quality of life, functional status, and resource utilization over months to years. The studies enroll advanced heart failure patients who meet criteria for transplantation or durable assist devices, including those with comorbidities that influence candidacy decisions. Findings inform clinicians and transplant programs about patient selection and timing decisions, and inform payers and hospitals about downstream costs and expected trajectories linked to an index hospitalization coded under this DRG.
Post-discharge outcomes and readmission reduction trials: These pragmatic trials evaluate care-transition interventions such as structured discharge planning, remote hemodynamic monitoring, telehealth follow-up, and outpatient anticoagulation or infection surveillance programs aimed at reducing 30- and 90-day readmissions, device-related complications, and graft rejection episodes. The participant pool consists of recent heart transplant recipients and patients discharged with an implanted assist device, including those with varying social support and frailty levels that impact post-acute care needs. This research is critical for providers to identify effective outpatient management pathways that improve long-term outcomes and for payers to understand interventions that can lower costly readmissions and post-acute care expenditures associated with this DRG.

Heart Transplant or Implant of Heart Assist System without MCC: Inpatient Reimbursement Overview

003-ECMO-OR-TRACHEOSTOMY-WITH-MV-96-HOURS-OR-PRINCIPAL-DIAGNOSIS-EXCEPT-FACE-MOUTH-AND-NECK-WITH-MAJOR-O-R-PROCEDURES

ECMO or Tracheostomy with MV >96 Hours: Inpatient Reimbursement Overview

004-TRACHEOSTOMY-WITH-MV-96-HOURS-OR-PRINCIPAL-DIAGNOSIS-EXCEPT-FACE-MOUTH-AND-NECK-WITHOUT-MAJOR-O-R-PROCEDURES

Tracheostomy with Mechanical Ventilation >96 Hours: Inpatient Reimbursement Overview

005-LIVER-TRANSPLANT-WITH-MCC-OR-INTESTINAL-TRANSPLANT

Liver Transplant with MCC or Intestinal Transplant: Inpatient Reimbursement Overview

006-LIVER-TRANSPLANT-WITHOUT-MCC

Liver Transplant without Major Complication or Comorbidity: Inpatient Reimbursement Overview

007-LUNG-TRANSPLANT

Lung Transplant: Inpatient Reimbursement Overview

008-SIMULTANEOUS-PANCREAS-AND-KIDNEY-TRANSPLANT

Simultaneous Pancreas and Kidney Transplant: Inpatient Reimbursement Overview

010-PANCREAS-TRANSPLANT

Pancreas Transplant: Inpatient Reimbursement Overview

011-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-MCC

Tracheostomy/Laryngectomy with MCC: Inpatient Reimbursement Overview

012-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-CC

Tracheostomy and Laryngectomy with CC: Inpatient Reimbursement Overview

Showing 1–10 of 16

Frequently Asked Questions

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

National Payment Rates

Mean Rates by Payer — National — DRG 001

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$330K	$1.5M	$280K	2K

Patient Population

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 001

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska at a mean of $490K, while Anthem and Blue Cross Blue Shield are tied as the lowest payers at a mean of $440K.
The statewide mean range spans from $440K to $490K, a relatively tight band compared with national variability; Alaska’s highest mean ($490K) modestly exceeds the national mean benchmarks shown but the lowest means ($440K) align with national medians, indicating limited upside in the market.

Clinical Trials

Perioperative management and device optimization trials: These studies focus on immediate intraoperative and early postoperative strategies for heart transplant recipients and patients receiving durable or temporary mechanical circulatory support devices, investigating protocols for anticoagulation timing, hemodynamic support algorithms, infection prophylaxis, and strategies to minimize right ventricular failure after device implantation. The patient population includes adults undergoing orthotopic heart transplantation or implantation of left ventricular assist devices (LVADs) or temporary extracorporeal support, often with multiple organ dysfunction or high surgical risk. Results are relevant to providers for improving survival and complication rates in the index hospitalization and to payers because optimized perioperative protocols can reduce intensive care length of stay, device-related complications, and readmissions that drive high costs under this DRG.
Comparative effectiveness studies of long-term support versus transplantation candidacy: These trials compare outcomes between patients who proceed to durable mechanical circulatory support as destination therapy or bridge-to-transplant versus those listed for transplantation, assessing survival, quality of life, functional status, and resource utilization over months to years. The studies enroll advanced heart failure patients who meet criteria for transplantation or durable assist devices, including those with comorbidities that influence candidacy decisions. Findings inform clinicians and transplant programs about patient selection and timing decisions, and inform payers and hospitals about downstream costs and expected trajectories linked to an index hospitalization coded under this DRG.
Post-discharge outcomes and readmission reduction trials: These pragmatic trials evaluate care-transition interventions such as structured discharge planning, remote hemodynamic monitoring, telehealth follow-up, and outpatient anticoagulation or infection surveillance programs aimed at reducing 30- and 90-day readmissions, device-related complications, and graft rejection episodes. The participant pool consists of recent heart transplant recipients and patients discharged with an implanted assist device, including those with varying social support and frailty levels that impact post-acute care needs. This research is critical for providers to identify effective outpatient management pathways that improve long-term outcomes and for payers to understand interventions that can lower costly readmissions and post-acute care expenditures associated with this DRG.

Heart Transplant or Implant of Heart Assist System without MCC: Inpatient Reimbursement Overview

003-ECMO-OR-TRACHEOSTOMY-WITH-MV-96-HOURS-OR-PRINCIPAL-DIAGNOSIS-EXCEPT-FACE-MOUTH-AND-NECK-WITH-MAJOR-O-R-PROCEDURES

ECMO or Tracheostomy with MV >96 Hours: Inpatient Reimbursement Overview

004-TRACHEOSTOMY-WITH-MV-96-HOURS-OR-PRINCIPAL-DIAGNOSIS-EXCEPT-FACE-MOUTH-AND-NECK-WITHOUT-MAJOR-O-R-PROCEDURES

Tracheostomy with Mechanical Ventilation >96 Hours: Inpatient Reimbursement Overview

005-LIVER-TRANSPLANT-WITH-MCC-OR-INTESTINAL-TRANSPLANT

Liver Transplant with MCC or Intestinal Transplant: Inpatient Reimbursement Overview

006-LIVER-TRANSPLANT-WITHOUT-MCC

Liver Transplant without Major Complication or Comorbidity: Inpatient Reimbursement Overview

007-LUNG-TRANSPLANT

Lung Transplant: Inpatient Reimbursement Overview

008-SIMULTANEOUS-PANCREAS-AND-KIDNEY-TRANSPLANT

Simultaneous Pancreas and Kidney Transplant: Inpatient Reimbursement Overview

010-PANCREAS-TRANSPLANT

Pancreas Transplant: Inpatient Reimbursement Overview

011-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-MCC

Tracheostomy/Laryngectomy with MCC: Inpatient Reimbursement Overview

012-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-CC

Tracheostomy and Laryngectomy with CC: Inpatient Reimbursement Overview

Showing 1–10 of 16

Frequently Asked Questions

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

Sign up for drg 001 policy alerts

DRG 001 Overview

OpenPayer

Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

Sign up for drg 001 policy alerts

DRG 001 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

Sign up for drg 001 policy alerts

DRG 001 Overview

Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

Sign up for drg 001 policy alerts

DRG 001 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

What clinical scenarios does DRG 001 cover?

How does coding affect assignment to DRG 001 and reimbursement?

Why is DRG 001 important for Medicare payment determinations and hospital financial planning?

What does the market benchmark data indicate about reimbursement variability for DRG 001?

What types of clinical research are relevant to care and costs for patients in DRG 001?

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

What clinical scenarios does DRG 001 cover?

How does coding affect assignment to DRG 001 and reimbursement?

Why is DRG 001 important for Medicare payment determinations and hospital financial planning?

What does the market benchmark data indicate about reimbursement variability for DRG 001?

What types of clinical research are relevant to care and costs for patients in DRG 001?

References